Life Sciences

  • April 22, 2026

    Oura Hit With New Patent Suit Over Fitness Wearables

    Zepp Health has hit Oura Health with a lawsuit in the Eastern District of Texas accusing the Finnish company of infringing a series of patents on wearable fitness devices, the latest salvo in a wider patent fight between the companies.

  • April 22, 2026

    Ex-Conn. Prosecutor Fights Drug Co. Bid To Appeal DQ Denial

    Insurers Humana Inc. and Molina Healthcare Inc. urged a federal judge to turn down a group of generic-drug makers' request for an immediate trip to the Third Circuit, arguing the drugmakers' bid for a second chance to disqualify Connecticut's former assistant attorney general from an antitrust case was not qualified for an interlocutory appeal.

  • April 22, 2026

    4 Firms Build Amneal's Up To $1.1B Kashiv Biosimilars Buy

    Biopharmaceutical company Amneal Pharmaceuticals Inc. on Wednesday unveiled plans to acquire biosimilars-focused Kashiv BioSciences LLC in a deal worth up to $1.1 billion that was built by four law firms.

  • April 22, 2026

    Chancery Sends Masimo Ex-CEO Pay Fight To California

    The Delaware Chancery Court sided with former Masimo Corp. CEO Joe E. Kiani in his fight with the global medical technology company, dismissing the company's lawsuit over a disputed $450 million severance package and ruling that the case must proceed in California, not Delaware.

  • April 21, 2026

    Armistice Capital Head Calls COVID Stock Rise 'Fun,' 'Lucky'

    Armistice Capital's founder defended his hedge fund Tuesday from claims it pump-and-dumped $250 million in Vaxart stock during the COVID-19 pandemic, telling a California federal jury that he and his fund got "lucky" and that the stock's rapid surge was "fun."

  • April 21, 2026

    Merck Beats Minn. Hockey Player's Talc Mesothelioma Claims

    A Chicago jury has found Merck & Co. not liable for a hockey player's mesothelioma allegedly caused by the Dr. Scholl's talc foot powder he used regularly for years.

  • April 21, 2026

    Biotech Co. Investors Clash Over 'Self-Dealing' Claim

    Attorneys for a biopharmaceutical and technology company stockholder and a group of venture investors sharply disagreed Tuesday over whether a financing deal was a lifeline for a struggling company or a self-serving maneuver that enriched insiders, as they argued a motion to dismiss the derivative suit in the Delaware Chancery Court.

  • April 21, 2026

    Congress Rallies More For Bills On Copyrights Than Patents

    There have been more intellectual property bills floated in Congress that are supportive of copyright rights than patent rights, according to a new report looking at how lawmakers treat the IP system.

  • April 21, 2026

    Amgen Faces ERISA Suit Over Health Plan Tobacco Surcharge

    A former Amgen Inc. employee filed a proposed class action in California federal court Tuesday alleging the biotech company discriminatorily imposes an "egregiously high" $150-a-month surcharge on employees who use tobacco products, while failing to adequately notify them of reasonable pathways to avoid the fees, in violation of federal benefits law.

  • April 21, 2026

    Pfizer, Dexcel Take 2 Patents Off Table For Bench Trial

    Drugmaker Pfizer and an Israeli competitor that is seeking to create a generic version of a Pfizer heart medication said Tuesday they have reached an agreement to remove two asserted patents from a trial set to start next week.

  • April 21, 2026

    Fed. Circ. Keeps Banner Witcoff And Saiber Off Patent Case

    The Federal Circuit kept intact the disqualification of two law firms from a patent ownership fight on Tuesday, saying it had not been shown a district judge made a clear error in removing them.

  • April 21, 2026

    Pot Management Co. Says It's Allowed Biz Tax Deduction

    A California-based management company linked to cannabis operations is challenging the IRS over a $4.2 million tax bill, according to a U.S. Tax Court petition, arguing that the company does not traffic in controlled substances that would otherwise bar it from claiming business deductions.

  • April 21, 2026

    Squires Stands By Ending Skincare IPR Over ITC Overlap

    U.S. Patent and Trademark Office Director John Squires has shot down Sinclair Pharma Ltd.'s request to revive its challenge to Hydrafacial LLC's skin treatment patent, which the director had terminated based on related proceedings at the U.S. International Trade Commission.

  • April 21, 2026

    Novo Nordisk Unit Can't Slip Former Exec's Sex, Age Bias Suit

    A Novo Nordisk unit must face a former finance director's lawsuit claiming she was fired because she was an older woman who complained about a male co-worker's behavior, with a North Carolina federal judge ruling her allegations were detailed enough to stay in court.

  • April 21, 2026

    Purdue Pharma Sentencing Punted For In-Person Attendance

    A New Jersey federal judge delayed Oxycontin maker Purdue Pharma's criminal sentencing by a week, saying rescheduling would give an in-person attendance option to hundreds of observers who tuned in virtually Tuesday.

  • April 21, 2026

    Ga. Justices Confront Fed, State Power Divide In Bio-Lab Suit

    Georgia's highest court seemed to struggle Tuesday with whether it had the authority to tell a federal judge if residents suing chlorine products company Bio-Lab Inc. over the aftermath of a 2024 fire could ask for medical monitoring as part of their class action.

  • April 21, 2026

    Philly Zantac Judge Again Declines To Recuse From Cases

    A Philadelphia judge overseeing the Zantac mass tort litigation against GlaxoSmithKline has once again denied a motion to recuse himself from the cases, claiming that his wife's affiliation with a firm representing a defendant in the litigation did not present a conflict that required him to step away.

  • April 20, 2026

    Armistice Head Testifies He Accidentally Deleted Texts

    Armistice Capital's founder, who is facing investor claims that the hedge fund dumped its artificially inflated shares in pharmaceutical company Vaxart for $250 million, told a California federal jury Monday that during a physical therapy session held over Skype, he accidentally deleted key text messages with another Armistice executive.

  • April 20, 2026

    Beasley Allen Pro Hac Vice Revoked In Philly J&J Talc Cases

    A Pennsylvania state court has booted Beasley Allen Law Firm attorneys from representing consumers in nine cases that link Johnson & Johnson's talcum powder to ovarian cancer, saying their pro hac vice admission was inappropriate given the firm's dealings with an attorney who previously represented the company.

  • April 20, 2026

    Quinn Emanuel May Face More Sanctions In Guardant Fight

    Guardant Health Inc. urged a California federal judge on Monday to make Quinn Emanuel pay nearly $1.3 million on top of $3 million in sanctions already imposed over misrepresentations lawyers made representing its rival Natera Inc., prompting the judge to criticize Quinn Emanuel lawyers for making distinctions so fine they veer into misrepresentation.

  • April 20, 2026

    Philip Morris Unfairly Gains From Label Ruling, 11th Circ. Told

    Philip Morris cannot be the only company allowed to not follow a rule requiring cigarette makers to add graphic warnings to their labels, R.J. Reynolds and a coalition of tobacco businesses have told the Eleventh Circuit, suggesting that consumers might assume its cigarettes are safer than theirs.

  • April 20, 2026

    ImmunityBio Stock Fell After FDA Letter, Derivative Suit Says

    Biotechnology company ImmunityBio Inc.'s stock slipped by 21% after misleading statements on a podcast by the company's founder about its lead cancer drug prompted the issuance of a warning letter from the U.S. Food and Drug Administration, according to a shareholder derivative suit in California federal court.

  • April 20, 2026

    SEC Says Adviser Traded On Firm Clients' Confidential Info

    The U.S. Securities and Exchange Commission sued an ex-investment advisory firm associate in Manhattan federal court on Monday, accusing him of using a close relative's brokerage account to trade ahead of market-moving announcements by three biopharmaceutical and biotechnology companies that his firm was researching.

  • April 20, 2026

    PFAS Plaintiffs Say Midcase Appeal Would 'Derail' Litigation

    Georgia residents accusing carpet and chemicals manufacturers of contaminating their properties with forever chemicals urged a state court to reject Shaw Industries' bid to appeal the recent nondismissal of their claims, arguing the request is the carpet company's latest "attempt to derail this litigation."

  • April 20, 2026

    PBMs Fail To Freeze Discovery In Mich.'s Drug-Pricing Case

    A pending motion to dismiss the Michigan attorney general's drug-pricing case against multiple pharmacy benefit managers does not preclude the PBMs from handing over agreements between PBMs and pharmacies to the state, a federal judge said in a motion hearing Monday.

Expert Analysis

  • How Recent Del. Rulings Clarify M&A Deal Fraud Carveouts

    Author Photo

    Two recent Delaware decisions have provided clarity regarding when a party can or cannot rely on representations made during the course of an M&A transaction, particularly on the scope and enforceability of antireliance provisions, and on representations they knew or should have known were false, says Anthony Boccamazzo at Olshan Frome.

  • High Court's 'Skinny Label' Case May Tackle Wider Questions

    Author Photo

    The U.S. Supreme Court's upcoming decision in Hikma v. Amarin will have important ramifications for broader debates over what defines a generic version of a drug, and the pending case is already altering patent practice, say attorneys at Taft.

  • Aligning Microsoft Tools With NYC Bar AI Recording Guidance

    Author Photo

    The New York City Bar Association’s recently issued formal opinion, providing ethical guidance on artificial intelligence-assisted recording, transcription and summarization, raises immediate questions about data governance and e-discovery for companies that use Microsoft 365 and Copilot, say Staci Kaliner, Martin Tully and John Collins at Redgrave.

  • FDA's Biosimilarity Guidance Holds Uncertain Implications

    Author Photo

    The U.S. Food and Drug Administration's new draft guidance aimed at simplifying the biosimilarity demonstration process may not be enough to overcome the barriers that have historically constrained biosimilar competition, and could affect biosimilar access in unexpected ways, say analysts at Analysis Group.

  • Unpacking Key Themes From NY's New Healthcare Strategy

    Author Photo

    New York Gov. Kathy Hochul's 2026 State of the State agenda, read together with the state's fiscal year 2027 executive budget, reflect a clear framework to utilize Medicaid as the state's operating platform for healthcare reform, say attorneys at Sheppard.

  • 5 Different AI Systems Raise Distinct Privilege Issues

    Author Photo

    A New York federal court’s recent U.S. v. Heppner decision, holding that a defendant’s use of Claude was not privileged, only addressed one narrow artificial intelligence system, but lawyers must recognize that the spectrum of AI tools raises different confidentiality and privilege questions, says Heidi Nadel at HP.

  • Opinion

    AI-Assisted Arbitration Needs Safeguards To Ensure Fairness

    Author Photo

    As tribunals and arbitral institutions increasingly use artificial intelligence tools in their decision-making processes, ​​​​​​​clear disclosure standards and procedural safeguards are necessary to ensure that efficiency gains do not erode the fairness principles on which arbitration depends, says Alexander Lima at Wesco International.

  • Trans Care Enforcement Landscape Is Evolving Quickly

    Author Photo

    The recent coordinated federal effort to reshape pediatric gender-affirming care through enforcement and funding pressure has created a rapidly evolving regulatory environment marked by shifting risk assessments and potential downstream market effects for healthcare institutions and life sciences companies, say attorneys at Arnall Golden.

  • Series

    Playing Piano Makes Me A Better Lawyer

    Author Photo

    Playing piano and practicing law share many parallels relating to managing complexity: Just as hearing an entire musical passage in my head allows me to reliably deliver the message, thinking about the audience's impression helps me create a legal narrative that keeps the reader engaged, says Michael Shepherd at Fish & Richardson.

  • 3 Cases Highlight SEC Distinction Between Exec, Co. Liability

    Author Photo

    Three recent enforcement actions against Spero Therapeutics, Lottery.com and Archer-Daniels-Midland demonstrate that while public companies are subject to liability for misrepresentations, the U.S. Securities and Exchange Commission is focused on individual liability when disclosure violations involve so-called half-truths, say attorneys at Cooley.

  • AI-Generated Doc Ruling Guides Attys On Privilege Risks

    Author Photo

    A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.

  • The Law Firm Merger Diaries: Leadership Strategy After Day 1

    Author Photo

    For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.

  • Record FCA Recoveries Signal Intensified Healthcare Focus

    Author Photo

    In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.

  • Fed. Circ. In Jan.: On The Validity Of Expert Testimony

    Author Photo

    The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.

  • Calif.'s Civility Push Shows Why Professionalism Is Vital

    Author Photo

    The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.